Keyword: Avalanche Biotechnologies

Salzman stepped down as CEO and president by “mutual determination,” while CMO Countouriotis resigned after less than one year in the job.

Adverum Biotechnologies has delayed the start of a Phase I/II trial of its alpha-1 antitrypsin deficiency gene therapy by 12 months.